Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsValganciclovir results in improved oral absorption of ganciclovir in liver transplant recipientsNovel therapeutic approaches for various cancer types using a modified sleeping beauty-based gene delivery systemProspective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation.Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsManagement of cytomegalovirus infection and disease in liver transplant recipients.Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitroPrevention of cytomegalovirus disease in recipients of solid-organ transplants.Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.Epidemiology of infections after solid-organ transplantation.Prevention of infections in solid organ transplant recipients.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Current concepts on cytomegalovirus infection after liver transplantationOral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.Liver transplantation in the UK.Human cytomegalovirus terminase as a target for antiviral chemotherapy.Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir.Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected womenInfections in solid-organ transplant recipientsHuman embryonic stem cells: a potential source for cellular therapy.Antimicrobial prophylaxis in solid-organ transplantation.Isolated unilateral cytomegalovirus retinitis: a rare long-term complication after pediatric liver transplantation.Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature.Qualitative and semiquantitative polymerase chain reaction testing for cytomegalovirus DNA in serum allows prediction of CMV related disease in liver transplant recipients.Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis.Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation.Cytomegalovirus infection and unusual early graft dysfunction in a renal transplant recipient.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.Cytomegalovirus infection with perineal pain after living donor liver transplantation: report of four cases.Management of cytomegalovirus infection in solid-organ transplant recipients.Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms.Cytomegalovirus infection after liver transplantation: current concepts and challenges.Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
P2860
Q24200697-86FB5F3A-FABF-4D45-9C7E-3669887EA692Q24200991-2BE2E308-7C43-4099-8D4F-DAD27B83F716Q24243124-342F17D1-C9A0-4BC5-A163-F809887594F8Q24244606-066497EA-DBFF-4F16-BF04-4AF66F7675C7Q28344757-824B9702-F2FC-49F5-9B3E-CA7F3C060B83Q28660424-6B8AA970-4B3E-4152-9065-29A0301B5C09Q33205085-93C1393B-89DF-4CA9-9C4D-7568C3A41A5FQ33364367-9A2A6205-8DB8-4468-BD3C-58E68879C29FQ33812425-767144B2-4B0A-419F-98E9-4405C7BB3F2AQ33845124-EE4BDC50-5076-4981-8C56-F8C251CA3108Q34111476-51D6D6A9-1AEC-4904-8C24-8C65D6527CE3Q34142019-7BE67E7D-6C79-4C76-AC16-1C70C292674DQ34191785-CBB95C50-A5B7-4CEE-892A-1B82F5C3D6D9Q34271651-D1284D70-3496-4EBE-8CF8-514DE4387C3AQ34294796-F68DA0BF-19CC-478E-AAFE-2EF65B02C9CAQ34294851-BBDD48A7-5766-497C-A6A8-67B48A35A256Q34390310-1C2237D8-0C88-4343-B63E-A9D9E08BC328Q34481742-609CD094-8197-448A-A500-98042B721EB6Q34512132-AA9E29C0-C846-4274-ABA3-E9CFF58A3427Q34580776-962A2DB3-B23B-4F18-84C2-AFCB2B3B6A79Q34918468-E7DD835B-5478-4321-B001-D758466B3AB9Q35087763-D812EF3A-518A-4452-9E9A-4743C5BCA805Q35376486-AD86E957-5C35-4EE8-9C4D-AD8FDD7A90B2Q35661046-454709B7-D268-4FF1-91BD-2A1BF580BE0CQ35917546-1F271362-74E4-4670-83AF-B7A97A63BD24Q36288302-AA197039-8233-4019-BE2F-5C8706A31AD3Q37034498-ACD32B34-19C8-4487-B546-287D8CDA8421Q37229975-DF0E9ECB-1CE5-4778-A1DC-7B4A5378FF6EQ37825594-9210494E-B6E3-41F2-9224-67A2FBD7788EQ38293175-60378B5D-C339-442B-A1B6-A7653AB27CD3Q39405795-4B4D63B4-79F8-407C-B28A-6EF639B66E8EQ39455215-FA3DD7CE-4638-44EA-A68A-A605BA983608Q39681707-931D0D63-FDED-4730-9155-46707C1E20D2Q40426465-2FF98A77-65AF-4026-8FDE-B90B6A14FE32Q40457321-93AD9B3B-69C5-4425-8C84-BCC2F6EB4561Q41351279-D737D194-A136-4B88-9E4B-48986FDF7B8DQ41439136-C62E0CB9-E5E8-427C-B380-239C834D8447Q41471865-3871610E-FDF4-433D-B503-71B7607C81F6Q42549311-E3DB9CA6-A9F3-40FC-9B53-7475A89C7AD1Q43894083-F7C521F6-EE58-4442-AA93-E047FE7D35D0
P2860
Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Randomised comparison of ganci ...... n liver-transplant recipients.
@ast
Randomised comparison of ganci ...... n liver-transplant recipients.
@en
type
label
Randomised comparison of ganci ...... n liver-transplant recipients.
@ast
Randomised comparison of ganci ...... n liver-transplant recipients.
@en
prefLabel
Randomised comparison of ganci ...... n liver-transplant recipients.
@ast
Randomised comparison of ganci ...... n liver-transplant recipients.
@en
P2093
P1433
P1476
Randomised comparison of ganci ...... n liver-transplant recipients.
@en
P2093
P356
10.1016/S0140-6736(95)92110-9
P407
P577
1995-07-01T00:00:00Z